Investigating how SETD7 helps prevent prostate cancer progression and therapy resistance
Official title: Noncanonical activities of SETD7 in preventing prostate cancer progression andtherapy resistance
Funded at University of Massachusetts Boston · NIH-11049260 · Data updated 2026-11-12
This study is looking at how a protein called SETD7 affects prostate cancer and how it might change the way well-known treatments work, with the goal of finding better options for patients dealing with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Massachusetts Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 5, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $416,409 |
| NIH project number | 1R01CA282906-01A1 |
| Project ID | NIH-11049260 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who are undergoing or have undergone androgen deprivation therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have androgen receptor-related issues may not benefit from this research.
What this research studies
This research focuses on understanding the role of the SETD7 protein in prostate cancer, particularly how it influences the effectiveness of androgen deprivation therapies. The study examines the mechanisms by which SETD7 regulates other proteins involved in cancer progression and resistance to treatment. By analyzing cancer cells and their response to therapies, the research aims to uncover new insights that could lead to improved treatment strategies for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that enhance the effectiveness of existing prostate cancer treatments.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic regulators like SETD7 in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
University of Massachusetts Boston
Boston, United States Active
Researchers
- Principal investigator: Cai, Changmeng — University of Massachusetts Boston
- Study coordinator: Cai, Changmeng
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.